The Resource Benign prostatic hyperplasia (BPH) management in primary care : screening and therapy : final report February 2007, Mark Helfand, Tara Muzyk, Mark Garzotto, (electronic book)

Benign prostatic hyperplasia (BPH) management in primary care : screening and therapy : final report February 2007, Mark Helfand, Tara Muzyk, Mark Garzotto, (electronic book)

Label
Benign prostatic hyperplasia (BPH) management in primary care : screening and therapy : final report February 2007
Title
Benign prostatic hyperplasia (BPH) management in primary care
Title remainder
screening and therapy : final report February 2007
Statement of responsibility
Mark Helfand, Tara Muzyk, Mark Garzotto
Creator
Contributor
Subject
Language
  • eng
  • eng
Summary
Benign prostatic hyperplasia (BPH) causes urinary hesitancy and intermittency, weak urine stream, nocturia, frequency, urgency, and the sensation of incomplete bladder emptying. These symptoms, collectively called "lower urinary tract symptoms," or LUTS, can significantly reduce quality of life. Men with no symptoms or mild symptoms (AUA Symptom Index [SI] score of <7 points), and those who tolerate moderate symptoms well, may be managed without pharmacotherapy ("watchful waiting"). For those who have moderate or severe symptoms, medical treatments include alpha-1-selective adrenergic receptor (a-1-AR) antagonists, 5-alpha-reductase inhibitors (5-aRIs), or a combination therapy with one drug from each of these classes. This report addresses the following questions about treatment for BPH: For patients with BPH, what are the comparative benefits, harms, and efficacy of combination therapy with a 5-alpha-reductase inhibitor plus an alpha blocker versus either treatment alone? What are the comparative efficacy and harms of alpha-1-adrenergic antagonists? Are there subgroups of patients based on demographics (age, racial groups), other medications, or co-morbidities for which one treatment is more effective or associated with fewer adverse events?
Member of
Cataloging source
DNLM
http://library.link/vocab/creatorName
Helfand, Mark
Government publication
federal national government publication
Illustrations
illustrations
Index
no index present
Literary form
non fiction
Nature of contents
  • dictionaries
  • bibliography
http://library.link/vocab/relatedWorkOrContributorName
  • Muzyk, Tara
  • Garzotto, Mark
  • United States
Series statement
Evidence synthesis pilot program
http://library.link/vocab/subjectName
  • Prostatic Hyperplasia
  • Adrenergic alpha-1 Receptor Antagonists
  • 5-alpha Reductase Inhibitors
  • Drug Therapy, Combination
  • Treatment Outcome
Label
Benign prostatic hyperplasia (BPH) management in primary care : screening and therapy : final report February 2007, Mark Helfand, Tara Muzyk, Mark Garzotto, (electronic book)
Instantiates
Publication
Note
"Comparative effectiveness review."
Bibliography note
Includes bibliographical references
Color
multicolored
Control code
1549857
Dimensions
unknown
Form of item
online
Specific material designation
remote
Label
Benign prostatic hyperplasia (BPH) management in primary care : screening and therapy : final report February 2007, Mark Helfand, Tara Muzyk, Mark Garzotto, (electronic book)
Publication
Note
"Comparative effectiveness review."
Bibliography note
Includes bibliographical references
Color
multicolored
Control code
1549857
Dimensions
unknown
Form of item
online
Specific material designation
remote

Library Locations

Processing Feedback ...